CD247 and lymphoma: A total of three phase 1 and one phase 1/2 trials have been registered (clinicaltrials.gov: NCT02315118, NCT02776813, NCT03266692, and NCT03189836), three employing CD16(V158)-4-1BB/CD3ζ autologous T cells in combination with Rituximab against refractory or relapsed lymphoma, respectively with BCMA against relapsed or refractory multiple myeloma.